Welcome to our dedicated page for Danaher Corporation news (Ticker: DHR), a resource for investors and traders seeking the latest updates and insights on Danaher Corporation stock.
Danaher Corporation (NYSE: DHR) is a globally diversified conglomerate based in Washington, D.C., focusing primarily on life sciences and diagnostics. Founded in 1984 by Stephen and Mitchell Rales, the company has transitioned from a real estate organization into a leading player in the medical, industrial, and commercial products sectors.
Danaher designs, manufactures, and markets a variety of innovative products, particularly scientific instruments and consumables. The company has recently revamped its portfolio by divesting its environmental and applied solutions group, Veralto, in late 2023. This strategic move has allowed Danaher to concentrate its efforts on advancing health through science and technology.
Among Danaher's notable achievements is the acquisition of Abcam plc, which enhances its capabilities in proteomics—an expanding field within life sciences. The company is also known for its contribution to gene-editing therapies through a collaboration with the Innovative Genomics Institute (IGI), aiming to develop CRISPR-based treatments for various diseases.
Danaher's portfolio includes well-known subsidiaries like Beckman Coulter Life Sciences, Integrated DNA Technologies, and Aldevron. These subsidiaries focus on delivering innovative solutions in diagnostics, genomics, and biomanufacturing. For instance, Beckman Coulter's recent partnership with Curiox Biosystems aims to provide automated sample preparation for flow cytometry, enhancing research efficiency.
Financially, Danaher reported better-than-expected revenue in the fourth quarter of 2023, bolstered by strong performance in its life sciences and diagnostics segments. The company's strategic divestitures and acquisitions have positioned it for long-term growth and increased shareholder value.
Danaher’s ongoing projects include a collaboration with Cincinnati Children's Hospital to improve liver organoid technology for drug toxicity screening. This initiative is part of the Danaher Beacons program, which funds pioneering academic research to develop next-generation medical technologies. Another significant collaboration is with Johns Hopkins University, focusing on diagnosing mild traumatic brain injuries (TBI) using advanced biomarker panels.
Overall, Danaher's commitment to scientific excellence, innovation, and continuous improvement makes it a crucial player in advancing healthcare globally. With over 63,000 associates worldwide, Danaher is dedicated to improving quality of life and laying the groundwork for a healthier, more sustainable future.
Danaher Corporation (NYSE: DHR) has announced its upcoming quarterly earnings conference call for the fourth quarter of 2020, scheduled for January 28, 2021, at 8:00 a.m. ET. The call will last approximately one hour and will be available via webcast on Danaher's website. A replay will be accessible after the call until February 11, 2021. Additional related materials will be posted on the website at 6:00 a.m. ET on the call date.
Danaher Corporation (NYSE: DHR) announced the appointment of Dr. Jose-Carlos Gutierrez-Ramos as Senior Vice President and Chief Scientific Officer. Reporting directly to President and CEO Rainer M. Blair, Gutierrez-Ramos will lead Danaher’s science and technology strategy. A seasoned expert, he joins from Abbvie, where he was Head of Global Drug Discovery. His previous roles include leadership positions at Repertoire Immune Medicines and Pfizer, among others. Gutierrez-Ramos holds a Ph.D. in Immunology and extensive experience in academia and R&D.
Danaher Corporation (NYSE: DHR) appointed Jennifer L. Honeycutt as Executive Vice President, effective January 1, 2021. Honeycutt will oversee Beckman Coulter Life Sciences, Integrated DNA Technologies, and other key businesses. Previously, she served as Vice President and Group Executive for Pall and IDT in China, and President of Pall and Beckman Coulter. Her leadership is noted for driving growth within the Life Sciences platform. With 20 years at Danaher, she holds degrees in Chemistry and French, along with an MBA in Technology Management.
Danaher Corporation (NYSE: DHR) has declared a quarterly cash dividend of $0.18 per share for common stock, scheduled for payment on January 29, 2021 to shareholders of record as of December 28, 2020. Additionally, a dividend of $11.875 per share will be paid for its 4.75% Series A Mandatory Convertible Preferred Stock and $12.50 for the 5.00% Series B Mandatory Convertible Preferred Stock, both payable on January 15, 2021 to holders of record on December 31, 2020.
Danaher Corporation (NYSE: DHR) announced that President and CEO Rainer M. Blair will present at the Evercore ISI HealthCONx Conference on December 1, 2020, at 8:50 a.m. ET. The presentation will be available via audio webcast on www.danaher.com. Danaher is a global science and technology innovator focused on solving complex challenges in health care, environmental, and applied markets. The company operates over 20 businesses and employs more than 67,000 associates, united by the Danaher Business System and a mission to enhance quality of life worldwide.
Beckman Coulter has launched its Access SARS-CoV-2 IgG II assay, designed to measure antibody levels from past SARS-CoV-2 infections. This new assay allows clinicians to evaluate and track immune responses numerically, assisting in protective immunity research. The company is also filing for Emergency Use Authorization with the FDA and plans to ship the assay to U.S. customers. The assay boasts a high sensitivity (96.0%) and specificity (99.9%), and is compatible with existing workflows to enhance COVID-19 diagnostics.
Danaher Corporation (NYSE: DHR) announced that Executive Vice President and Chief Financial Officer, Matt McGrew, will present at the Wolfe Research Healthcare Conference on November 19, 2020, at 12:00 p.m. ET. The presentation will be available via simultaneous webcast on the Danaher website.
As a global innovator in science and technology, Danaher operates in healthcare, environmental, and applied markets, employing over 67,000 associates. For more information, visit www.danaher.com.
Beckman Coulter has launched its Access SARS-CoV-2 Immunoglobulin M (IgM) assay in CE Mark countries. The test exhibits 99.9% specificity and 98.3% sensitivity 15-30 days post-symptom onset, offering a positive predictive value of 95.5% in populations with a 3% disease incidence. This assay complements Beckman Coulter's suite of COVID-19 testing solutions, which include IgG assays and an antigen test under development. Beckman Coulter aims to address high testing demands by leveraging its advanced automation technology, capable of delivering over 15 million tests monthly.
Cytiva has launched new services aimed at supporting point-of-care diagnostic developers, enhancing speed to market for new tests. The initiative includes establishing new labs in Germany and China, and expanding existing facilities in Wales. A multi-million dollar investment will boost diagnostic capabilities and supply chain enhancements. Cytiva has played a pivotal role during the COVID-19 pandemic, aiding the testing of over 50 million individuals. This investment is part of a broader $500 million plan to expand manufacturing capacity over five years.
FAQ
What is the current stock price of Danaher Corporation (DHR)?
What is the market cap of Danaher Corporation (DHR)?
What does Danaher Corporation specialize in?
Who founded Danaher Corporation and when?
Where is Danaher Corporation headquartered?
What recent divestiture has Danaher Corporation made?
What are some of Danaher's notable subsidiaries?
What recent acquisition has enhanced Danaher's capabilities in proteomics?
What is the Danaher Beacons program?
What collaboration is Danaher involved in to improve liver organoid technology?
What is the focus of Danaher's partnership with Johns Hopkins University?
How does Danaher contribute to the field of gene-editing therapies?
